Novel Agents Beyond Immunomodulatory Agents and Phosphoinositide-3-Kinase for Follicular Lymphoma.
Sign Up to like & getrecommendations! Published in 2020 at "Hematology/oncology clinics of North America"
DOI: 10.1016/j.hoc.2020.03.002
Abstract: Follicular lymphoma is the most common indolent non-Hodgkin lymphoma. Although median overall survival rates exceed 12 years with rituximab, follicular lymphoma remains largely incurable. The growing understanding of the molecular drivers of lymphomagenesis and the tumor… read more here.
Keywords: lymphoma; agents beyond; novel agents; follicular lymphoma ... See more keywords